Genomic studies by Murphy et al. attributed drug-induced SAMS to genetic disposition, with increased risk correlating to transmembrane protein 9 (TMEM9) gene variants, reporting an odds ratio (OR) of 1.39 (95% CI: 1.24-1.55; p = 6.01 × 10−9). The gene discussed is TMEM9; the disease is short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.